Michelson Diagnostics secures GBP1.98m financing
Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence Tomography technology, has closed its Series A2 financing.
The round, which was oversubscribed, raised GBP1.98m (USD3.25m) from existing investors, led by Octopus Investments and supported by Catapult Venture Managers, London Business Angels and several business angels.
The funds will be used for several purposes including expanding VivoSight sales in Germany, where the system was launched in mid-2011 and where it is reimbursed for use in the diagnosis of non-melanoma skin cancer (NMSC), the commonest skin malignancy. The company will also invest further in the development of a compact, more portable second generation VivoSight System with an anticipated lower cost of manufacture and enhanced functionality. Part of the monies raised will be used to initiate US market access with a pilot clinical study planned. The company believes that the US is the largest single market for the VivoSight system.
VivoSight is a medical imaging system, which uses Michelson Diagnostics multi-beam OCT technology to non-invasively view all the layers of the skin in great detail for the first time.
VivoSight provides clinicians with real-time, high definition images of the skin through a fast, accurate and reliable imaging system. The company’s initial focus is in the diagnosis of non-melanoma skin cancer (NMSC), which is the most common skin cancer with approximately 3.5 million new cases in the US each year.
VivoSight currently has regulatory clearance in Europe and Australia, and FDA 510(k) clearance in the US. Following the launch, use of VivoSight in Germany has grown rapidly, with more than 2,500 scan procedures performed by December 2013 at ten clinics. The company is now entering the Australian and Swiss markets.
Jon Holmes, chief executive officer of Michelson Diagnostics, says: “I would like to thank our investors for their continued support; the completion of this financing concludes a year in which we have made real progress, especially in our market access in Germany. We now look forward to a very promising 2014 which will include the publication of Level 1 Clinical Evidence in the diagnosis of NMSC.”
Simon Andrews, a member of the ventures team at Octopus Investments, says: “The team at Michelson Diagnostics has really impressed us over the past 18 months. The market for non-invasive therapy is developing and we are very pleased to see the promising early results of the multi-centre study which should accelerate the adoption of VivoSight. The business has made excellent progress to date and we are excited about the next stage of its growth and development.”
Michelson Diagnostics was advised by Catalysis Capital Partners and Edwards Wildman Palmer UK and Octopus Investments were advised by Shoosmiths.
- By Category
- News from other sites
- Special Reports